Top Sertraline Brands You Should Consider

As mental health awareness continues to rise, the demand for effective medications such as sertraline, commonly prescribed for depression and anxiety disorders, remains high. Many pharmaceutical companies produce their own branded versions of this medication, each maintaining stringent standards of quality and efficacy. Some well-known brands and manufacturers of sertraline include Greenstone, Pfizer's generic label; Teva Pharmaceuticals, a global leader in generic drugs; and Aurobindo Pharma, known for its extensive range of generic medications. To explore more about these and other reputable brands, take a look at the detailed comparison below.

Illustration of sertraline

Best brands of sertraline in 2025

Zoloft

Zoloft, developed by Pfizer, is a leading selective serotonin reuptake inhibitor (SSRI) widely prescribed for treating major depressive disorder, obsessive-compulsive disorder, and other mental health conditions. The global sertraline HCl market, which includes Zoloft, was valued at US$ 1,385.9 million in 2022 and is expected to grow at a CAGR of 7.1% from 2022 to 2030. Zoloft's success has significantly contributed to the pharmaceutical industry, with over 40 million prescriptions in the U.S. alone in 2022. The introduction of generic alternatives has also made sertraline more accessible, but Pfizer remains a prominent force in the market. The increasing demand for mental health treatments drives the market growth, with Zoloft being a key player.

Lustral

Lustral, produced by Pfizer, is often regarded as one of the most effective and reliable brands of sertraline, with many users reporting consistent efficacy and minimal side effects. This brand has been a staple in the treatment of depression, anxiety disorders, and other mental health conditions, with a significant number of prescriptions filled annually; for instance, in 2022, sertraline prescriptions in the U.S. totaled nearly 40 million. The global sertraline market, which includes Lustral, is expected to grow at a CAGR of 7.1% from 2022 to 2030, driven by the increasing prevalence of mental disorders. User feedback often highlights Pfizer's Lustral as a preferred choice due to its consistent performance, even when compared to generic alternatives. This preference is reflected in the market's growth, with North America, where Pfizer is a major player, dominating the sertraline market. For more user experiences, visit the sertraline discussion forum.

Altruline

Altruline, a brand of sertraline by Pfizer, is renowned for its high-quality production and significant environmental improvements. Pfizer's innovative manufacturing process for sertraline, the active ingredient in Altruline, has doubled the product yield, reduced raw material use by 20-60%, and eliminated approximately 1.8 million pounds of hazardous materials annually. This green chemistry approach, recognized with the 2002 Presidential Green Chemistry Challenge Award, also reduced energy and water use and enhanced worker safety. At peak sales, Pfizer manufactured over 350 tons of sertraline hydrochloride per year, highlighting the scale and efficiency of their production. The new process has also minimized solvent waste, replacing harmful solvents like methylene chloride and tetrahydrofuran with more benign alternatives like ethanol.

Sertagen

Egis Pharmaceuticals, through its brand, is recognized as a significant producer of sertraline, a selective serotonin reuptake inhibitor (SSRI) used primarily for treating depression, anxiety disorders, and other mental health conditions. The company's investment in state-of-the-art production facilities, such as the new plants in Kormend, Hungary, enhances its capability to develop and manufacture high-quality generic drugs, including sertraline, with full control over all processes. The sertraline market, which Egis is a part of, is expected to grow at a CAGR of 3.90% from 2022 to 2029, driven by increasing demand and advanced healthcare infrastructure. Egis's commitment to innovation and quality ensures that its sertraline products meet stringent standards, making them reliable choices for patients. With a strong presence in Eastern European markets and expanding distribution agreements, Egis continues to strengthen its position in the pharmaceutical industry. To learn more about their advancements and products, visit the Egis Pharmaceuticals magazine.

Serlain

Torrent Pharma, a leading pharmaceutical company, is renowned for its high-quality sertraline products, contributing significantly to the global market. With a presence in over 50 countries, Torrent Pharma is a pioneer in niche marketing and holds a strong position in the CNS segment. The global sertraline market, valued at US$ 1,385.9 million in 2022, is expected to grow at a CAGR of 7.1% until 2030, driven by increasing prevalence of mental disorders. Torrent Pharma's international business, particularly in regions like Brazil and Germany, where it has the largest market share among Indian companies, underscores its market dominance. The company's commitment to sustainability and robust technical capabilities further enhance its reputation.

Serlift

Sertraline, marketed under various brands including Serlift by Sun Pharmaceutical, is a highly sought-after medication due to its efficacy in treating depression, anxiety disorders, panic disorder, and obsessive-compulsive disorder. Sun Pharmaceutical, the fourth largest specialty generic pharmaceutical company globally, boasts a strong presence in over 100 countries and generates significant revenue, with global revenues of US$ 5.4 billion. The company's extensive manufacturing capabilities, supported by 43 facilities, ensure high-quality and affordable medicines. The sertraline market, expected to grow at a CAGR of 3.90% from 2022 to 2029, is driven by increasing demand for antidepressants and rising awareness of mental health. With North America dominating the market due to well-developed healthcare infrastructure, Sun Pharmaceutical's Serlift is a key player in this expanding market. For more information about the company, visit the Sun Pharmaceutical website.

Serenata

Sertraline, commonly known by brand names such as Zoloft, is also produced by other manufacturers like Cipla under the brand name Serenata. Cipla's Serenata is recognized for its high bioavailability, estimated to be above 44%, and its effectiveness in treating various conditions including depression, anxiety disorders, panic disorder, and obsessive-compulsive disorder. The drug reaches steady-state concentrations after about one week of once-daily administration and is highly bound to serum proteins, approximately 98%-99%. Serenata, like other sertraline formulations, is metabolized primarily in the liver and has an elimination half-life of around 26 hours. Its market presence is significant, particularly in regions with well-developed healthcare infrastructure.

Serophene

Serophene, a brand by Aldaph SpA, is not specifically associated with sertraline production, but Aldaph SpA is a notable pharmaceutical company in Algeria. However, for sertraline, key producers include Pfizer, the original developer, and various generic manufacturers. The global sertraline market is expected to grow at a CAGR of 3.90% from 2022 to 2029, driven by increasing prevalence of mental health disorders and growing healthcare expenditure. In 2022, sertraline was prescribed nearly 40 million times in the U.S., highlighting its widespread use. The market is dominated by North America due to well-developed healthcare infrastructure and high disposable income.

Recalin

Recalin, if it were a brand associated with sertraline, would be part of a market where sertraline prescriptions have significantly increased, from over 28 million in 2004 to nearly 40 million in 2022 in the U.S.. The global sertraline market is valued at USD 1,385.9 million in 2022 and is expected to grow at a CAGR of 7.1% until 2030. Sertraline, primarily used as an SSRI, is effective in treating various mental health disorders, including depression, anxiety, and OCD. However, without specific data on Recalin, it is challenging to highlight its unique contributions. For more general information, visit Almirall's official website.

Tresleen

Sertraline, commonly known by the brand name Zoloft, is a highly prescribed antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class. Approved by the US FDA in 1991, sertraline is used to treat various psychiatric conditions, including major depressive disorder, obsessive-compulsive disorder, and premenstrual dysphoric disorder. In 2022, sertraline was prescribed nearly 40 million times in the U.S., highlighting its widespread use. It is known for its efficacy, with continuous dosing regimens often preferred for treating premenstrual symptoms. Sertraline's mechanism of action involves inhibiting serotonin reuptake, leading to an accumulation of serotonin in the central nervous system. For more detailed information, visit sertraline's profile on the National Center for Biotechnology Information.